Ann: Dimerix Successfully Passes Efficacy Interim Analysis, page-152

Thanks Dr T..

I think we have a lot of posters here spreading unsubstantiated fear by either lying or showing half baked truth.

Reality is that like any other company, the outcome can go either way. There is no rocket science in that and that's just the nature of clinical development.

Now Advanz didn't had visibility to P3 data as they signed before P3 interim results but they would have had more data from P2 study which none of us have.

However any new partner who will come in will have access to data from P3 study, more than what we see (of course not all data as only DSMB has access to it).

The next deal or two, specially in big markets will be a huge confidence boost to the SH as this just solidifies the confidence as their experts will go through all possible details available and made a decision based on their experience.

Until then, I am sure we will get a lot of ifs and buts on this forum sadly from people who post with a specific agenda.

Good luck to all genuine holders.